ClinicalTrials.Veeva

Menu

Molecular Imaging of Breast Cancer With Breast PET/CT

University of California (UC) Davis logo

University of California (UC) Davis

Status and phase

Terminated
Phase 1

Conditions

Breast Cancer

Treatments

Radiation: Positron emission tomography and computed tomography

Study type

Interventional

Funder types

Other

Identifiers

NCT00584753
200715040

Details and patient eligibility

About

This study is a feasibility study to determine if a combined breast PET/CT scanner can image malignant functional activity while determining anatomical structure in the same clinical setting for patients with breast cancer. End-points of this study are whether women will accept the imaging position and timing, and whether functional properties of breast cancer can be imaged with this device. The secondary purpose of this study is to explore protocol parameters with a view to optimizing imaging performance whilst minimizing patient discomfort. Imaging results will be compared to histological samples to determine ground truth.

Full description

PET is literally a molecular imaging modality. In monitoring the patient's response to a specific chemotherapeutic regime, baseline and subsequent PET/CT scans can be used to quantitatively determine the therapeutic effect of the regime, using the standard uptake value (SUV), a common metric in PET imaging. The breast PET/CT system will facilitate molecular imaging of breast cancer using a number of radiolabeled molecules, available both commercially (18-FDG) and from the research environment.

Enrollment

4 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Normal Adult Volunteers
  • Female, at least 18 years of age
  • Ability to lie motionless for up to 20 minutes

Patient Volunteers

  • Female, at least 18 years of age
  • Diagnostic findings from prior mammography highly suggestive of invasive breast carcinoma (BI-RADS category 5)
  • Not pregnant or breast-feeding
  • Ability to lie motionless for up to 20 minutes

Exclusion criteria

  • Normal Adult Volunteers

    • Inability to understand the risks and benefits of the study

Patient Volunteers

  • Recent breast biopsy
  • Diagnostic findings from prior mammography highly suggestive of noninvasive ductal or lobular carcinoma
  • Uncontrolled diabetes
  • Diabetic and blood sugar level > 200 mg/dL
  • Positive urine pregnancy test or currently breast-feeding
  • Inability to understand the risks and benefits of the study

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

4 participants in 3 patient groups

1
Other group
Description:
Normal volunteers
Treatment:
Radiation: Positron emission tomography and computed tomography
Radiation: Positron emission tomography and computed tomography
Radiation: Positron emission tomography and computed tomography
2
Active Comparator group
Description:
Breast PET/CT scan
Treatment:
Radiation: Positron emission tomography and computed tomography
Radiation: Positron emission tomography and computed tomography
Radiation: Positron emission tomography and computed tomography
3
Active Comparator group
Description:
Whole body and breast PET/CT
Treatment:
Radiation: Positron emission tomography and computed tomography
Radiation: Positron emission tomography and computed tomography
Radiation: Positron emission tomography and computed tomography

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems